Table 3.
Clinical Trials for BTC Targeted Therapy Targeting ErbB Family
| Target | Drugs | ClinicalTrials.gov Identifier | Status | Phase | Disease | Number of Patients | Design |
|---|---|---|---|---|---|---|---|
| EGFR | Erlotinib | NCT01149122 | Completed | III | BTC | 268 | Erlotinib plus GEMOX vs GEMOX |
| NCT03110484 | Not yet recruiting | II | BTC | 38 | Erlotinib plus Pemetrexed | ||
| NCT00987766 | Completed | I | BTC, Other solid tumor types | 28 | Erlotinib plus GEMOX | ||
| NCT00266097 | Completed | I | BTC, Pancreatic Cancer | 23 | Erlotinib + GEMOX + Radiation vs GEMOX + Radiation | ||
| NCT02091141 | Recruiting | II | BTC, Salivary cancer, Bladder Cancer | 765 | Erlotinib | ||
| NCT00033462 | Completed | II | BTC | 78 | Erlotinib | ||
| NCT00350753 | Completed | II | BTC | 126 | Erlotinib plus Bevacizumab | ||
| NCT01093222 | Completed | II | BTC | 40 | Erlotinib plus Sorafenib | ||
| NCT00955149 | Completed | I | CCA Primary Sclerosing Cholangitis | 6 | Erlotinib | ||
| NCT00356889 | Completed | II | BTC | 56 | Erlotinib plus Bevacizumab | ||
| NCT00397384 | Completed | I | BTC Other solid tumors | 43 | Erlotinib plus Cetuximab | ||
| Cetuximab | NCT01216345 | Completed | II | BTC | 30 | Cetuximab plus GEMOX | |
| NCT00552149 | Completed | II | BTC | 150 | Cetuximab plus GEMOX vs GEMOX | ||
| NCT01267344 | Completed | II | BTC | 122 | Cetuximab plus GEMOX vs GEMOX | ||
| NCT01247337 | Unknown | II | CCA | 100 | Cetuximab plus GEMOX plus Capecitabine | ||
| NCT00397384 | Completed | I | BTC, Other solid tumors | 43 | Cetuximab plus Erlotinib | ||
| NCT03768375 | Recruiting | II | BTC | 150 | Cetuximab plus GEMOX vs GEMOX | ||
| NCT02836847 | Recruiting | II | BTC | 152 | Cetuximab plus GEMOX vs GEMOX | ||
| NCT00747097 | Completed | II | BTC | 43 | Cetuximab plus Gemcitabine | ||
| Panitumumab | NCT01389414 | Completed | II | BTC | 89 | Panitumumab plus GEMOX vs GEMOX | |
| NCT01320254 | Completed | II | CCA | 93 | Panitumumab plus GEMCIS vs GEMCIS | ||
| NCT01206049 | Completed | II | CCA | 88 | Panitumumab plus Combination chemotherapy vs Bevacizumab plus Combination chemotherapy | ||
| NCT00948935 | Completed | II | BTC | 35 | Panitumumab plus Gemcitabine plus Irinotecan | ||
| NCT00779454 | Completed | II | CCA | 72 | Panitumumab plus GEMOX plus Capecitabine (Kras WT) vs GEMOX plus Capecitabine (Kras mutation) | ||
| NCT01308840 | Completed | II | BTC | 31 | Panitumumab plus GEMOX | ||
| Varlitinib (ASLAN001) | NCT02609958 | Completed | II | CCA | 32 | Varlitinib | |
| NCT03231176 | Active, not recruiting | II | BTC | 68 | Varlitinib plus Capecitabine | ||
| NCT03093870 | Active, not recruiting | II | BTC | 490 | Varlitinib plus Capecitabine vs Placebo plus Capecitabine | ||
| NCT02992340 | Recruiting | I II |
BTC | 204 | Varlitinib plus GEMCIS | ||
| NCT03082053 | Completed | I | BTC | 24 | Varlitinib vs Varlitinib plus Capecitabine | ||
| Gefitinib | NCT03768375 | Recruiting | II | BTC | 150 | Gefitinib plus GEMOX vs GEMOX | |
| NCT02836847 | Recruiting | II | BTC | 152 | Gefitinib plus GEMOX vs GEMOX | ||
| HER2 | Trastuzumab | NCT03613168 | Recruiting | II | BTC | 15 | Trastuzumab plus GEMCIS |
| NCT02999672 | Completed | II | CCA, Pancreatic cancer | 20 | Trastuzumab | ||
| NCT00004074 | Completed | I | Malignancies with HER2-Neu overexpressing | 15 | Trastuzumab plus IL12 | ||
| NCT03768375 | Recruiting | II | BTC | 150 | Trastuzumab plus GEMOX vs GEMOX | ||
| NCT02836847 | Recruiting | II | BTC | 152 | Trastuzumab plus GEMOX vs GEMOX | ||
| NCT02393248 | Recruiting | I II |
CCA, Other solid tumor types | 325 | Trastuzumab plus Pemigatinib vs Pemigatinib plus GEMCIS vs Pemigatinib plus Pembrolizumab vs Pemigatinib plus Docetaxel vs Pemigatinib plus INCMGA00012 | ||
| NCT02465060 | Recruiting | II | Malignancies with HER2 amplification | 6452 | Trastuzumab | ||
| NCT03185988 | Recruiting | II | BTC | 100 | Trastuzumab plus Chemotherapy | ||
| NCT02091141 | Recruiting | II | BTC, Salivary Cancer, Bladder Cancer | 765 | Trastuzumab plus Pertuzumab | ||
| Pertuzumab | NCT02091141 | Recruiting | II | BTC, Salivary Cancer, Bladder Cancer | 765 | Pertuzumab plus Trastuzumab | |
| NCT02465060 | Recruiting | II | Malignancies with HER2 amplification | 6452 | Pertuzumab plus Trastuzumab | ||
| EGFR&HER2 | Lapatinib | NCT00101036 | Completed | II | BTC | 57 | Lapatinib |
| NCT00107536 | Completed | II | BTC | 26 | Lapatinib | ||
| NCT03768375 | Recruiting | II | BTC | 150 | Lapatinib plus GEMOX vs GEMOX | ||
| NCT02836847 | Recruiting | II | BTC | 152 | Lapatinib plus GEMOX vs GEMOX | ||
| Afatinib | NCT02451553 | Recruiting | I | BTC, Pancreatic Cancer | 48 | Afatinib plus Capecitabine | |
| NCT02465060 | Recruiting | II | Malignancies with EGFR mutations | 6452 | Afatinib | ||
| Neratinib | NCT01953926 | Recruiting | II | Solid tumors with somatic HER2 or EGFR exon 18 mutations | 650 | Neratinib vs Neratinib plus Paclitaxel vs Neratinib plus Trastuzumab vs Neratinib plus Fulvestrant plus Trastuzumab |